Pathophysiology
- Beta-amyloid plaques: Abnormal deposits of amyloid-beta protein fragments accumulate between neurons, disrupting cell-to-cell communication and triggering inflammatory responses that damage surrounding tissue
- Neurofibrillary tangles: Twisted strands of hyperphosphorylated tau protein inside neurons disrupt intracellular transport, starving the neuron of nutrients and causing cell death
- Neurotransmitter depletion: Progressive loss of acetylcholine (ACh) — the basis for cholinesterase inhibitor treatment (donepezil/Aricept, rivastigmine/Exelon, galantamine/Razadyne). Also affects norepinephrine and serotonin
- Brain atrophy: Measurable brain shrinkage beginning in the hippocampus (memory) and spreading to the cerebral cortex (higher functions). Enlarged ventricles visible on imaging
- Staged progression: Mild (memory lapses, word-finding difficulty, personality changes) to moderate (inability to perform ADLs, confusion, agitation, wandering) to severe (loss of speech, inability to recognize family, incontinence, bedbound)
- Risk factors: Age (greatest risk factor), APOE-e4 allele, family history, female sex, Down syndrome, cardiovascular disease, head trauma history, physical inactivity, social isolation
Signs and Symptoms
Staged Progression
| Stage | Key Features |
|---|---|
| Mild | Short-term memory loss, word-finding difficulty, misplacing objects, personality changes, reduced judgment |
| Moderate | Inability to perform ADLs independently, confusion about time and place, agitation, wandering, sundowning (evening confusion), inability to learn new information |
| Severe | Loss of speech, inability to recognize family, incontinence, dysphagia, bedbound, vulnerability to infections (pneumonia is the most common cause of death) |
Red Flags
- Acute confusion in a previously stable AD client: May indicate urinary tract infection, medication change, dehydration, or stroke — not simply disease progression. Requires medical evaluation
- Falls: Spatial disorientation and gait changes create high fall risk. Report new falls to caregivers
- Dysphagia: Choking risk increases in moderate-severe stages. Observe for coughing or wet voice quality during and after treatment
- Aggressive behavior: May indicate pain, fear, or environmental overstimulation rather than willful aggression. Do not proceed with treatment during active aggression
Massage Therapy Considerations
- Benefits: Reduces agitation and anxiety (one of the most significant benefits of MT for AD). Decreases cortisol levels. Improves mood and promotes relaxation. Provides human touch (often lacking in institutional care). May improve sleep quality and reduce wandering
- Consent: In mild stages, the client may still provide informed consent — document capacity at each visit. In moderate-severe stages, obtain consent from the substitute decision-maker (power of attorney for personal care) and seek assent from the client (non-verbal willingness). If the client resists, do not proceed
- Session modifications: Shorter sessions (15-30 minutes) due to limited attention span. Simple, predictable routines. Consistent pressure without rapidly changing techniques. Calm environment with minimal stimulation
- Communication: Monitor facial expressions, body tension, and withdrawal as comfort indicators since verbal communication declines. Use simple, clear language. Re-establish rapport at each visit as the client may not remember the therapist
- Medications: Cholinesterase inhibitors may cause GI side effects and bradycardia. Memantine is generally well-tolerated. Both are less relevant to MT modifications than the behavioral aspects of the disease
- Fragile skin: Common in elderly clients with AD. Use gentle pressure and adequate lubrication
- Caregiver present: Having a familiar caregiver in the room during treatment reduces confusion and anxiety and helps verify consent
- Familiar therapist: Consistency reduces anxiety. The same therapist at the same time in the same room supports the client's remaining capacity for routine recognition
CMTO Exam Relevance
- Most common cause of dementia (60-80% of cases). Pathological hallmarks are beta-amyloid plaques and neurofibrillary tangles
- Consent capacity diminishes with disease progression. Substitute decision-maker required in moderate-severe stages
- Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) increase ACh. NMDA receptor antagonist (memantine) for moderate-severe AD
- Differentiate from vascular dementia (stepwise decline, focal signs), Lewy body dementia (visual hallucinations, parkinsonian features), and frontotemporal dementia (personality changes early, younger onset)
- Massage reduces agitation — a key therapeutic benefit tested on exams
Key Takeaways
- Alzheimer's disease is the most common cause of dementia, characterized by beta-amyloid plaques and neurofibrillary tangles causing progressive neuronal death.
- Massage therapy significantly reduces agitation, anxiety, and cortisol levels — one of the most evidence-supported benefits for this population.
- Consent must be obtained from a substitute decision-maker in moderate-severe stages. Seek assent from the client and do not proceed if the client resists.
- Session modifications include shorter duration (15-30 minutes), predictable routines, calm environment, and consistent therapist.
- Monitor non-verbal cues for comfort since verbal communication progressively declines.
- Acute confusion in a previously stable client may indicate a medical issue (UTI, dehydration, stroke), not just disease progression.